• Bile Acid Metabolism Subtypes Reveal CRC Prognostic Markers

  2026-06-01

  Feng et al. (2026) present an integrative subtyping of colorectal cancer (CRC) based on bile acid metabolism, identifying CLCA1, UGT2A3, and ZG16 as markers of immune dysfunction and poor prognosis. This approach offers refined biomarker-driven stratification and highlights the metabolic-immune interplay influencing CRC outcomes.

• Crizotinib Hydrochloride: ALK Kinase Inhibitor in Assembloid

  2026-06-01

  Crizotinib hydrochloride empowers researchers to dissect oncogenic signaling in patient-derived gastric cancer assembloid models, enabling nuanced study of tumor–stroma interactions and drug resistance. This guide translates recent experimental innovations into actionable workflows and troubleshooting strategies for maximizing assay fidelity.

• HotStart™ 2X Green qPCR Master Mix: Technical Guidance & QC

  2026-05-31

  HotStart™ 2X Green qPCR Master Mix addresses specificity and reproducibility challenges in SYBR Green-based real-time PCR for gene expression analysis, RNA-seq validation, and nucleic acid quantification. It is designed for researchers requiring minimized non-specific amplification and robust, accurate quantification. This reagent is not recommended for probe-based qPCR assays or non-thermal cycling applications.

• Vardenafil HCl Trihydrate: Precision in Proteoform-Driven PD

  2026-05-30

  This article explores how Vardenafil HCl Trihydrate empowers translational researchers to dissect proteoform-specific interactions in native signaling environments, advancing smooth muscle and erectile dysfunction models. Integrating mechanistic insights, recent proteomics breakthroughs, and practical guidance, we chart a path from rational assay design to clinical translation—offering a visionary outlook on next-generation PDE5 research.

• Dual Enzyme-Responsive Zwitterionic Peptides for Cancer Sele

  2026-05-29

  The referenced study introduces a peptide amphiphile system that leverages dual enzyme-responsiveness and zwitterionic self-assembly for highly selective cancer cell targeting. This innovative approach achieves a selectivity index of 64.1 and demonstrates potent in vivo efficacy with minimal toxicity, offering new avenues for precision peptide-based chemotherapeutics.

• Bleomycin Sulfate: Mechanistic and Benchmark Insights for Fi

  2026-05-29

  Bleomycin Sulfate is a validated DNA strand-break inducer and anticancer agent, widely used in pulmonary fibrosis research and oncology. Its mechanism involves metal-mediated DNA cleavage, yielding robust and tunable models for studying TGF-β/Smad and JAK-STAT pathway involvement in fibrotic and neoplastic diseases. APExBIO’s Bleomycin Sulfate (A8331) offers reproducible solubility, potency, and protocol adaptability for advanced preclinical workflows.

• Lopinavir Identified as Potent Inhibitor of MERS-CoV Replica

  2026-05-28

  de Wilde et al. conducted a systematic screen of FDA-approved compounds, revealing Lopinavir (ABT-378) as an effective inhibitor of Middle East respiratory syndrome coronavirus (MERS-CoV) replication in cell culture. This finding highlights the potential of drug repurposing for rapid antiviral intervention against emerging coronaviruses.

• iPSC-Derived Multilineage Organoids Reveal Pan-Tissue HEV In

  2026-05-28

  This study establishes induced pluripotent stem cell (iPSC)-derived organoids from liver, intestine, and brain as robust, physiologically relevant models for hepatitis E virus (HEV) infection. By supporting the full HEV life cycle and revealing tissue- and cell-type-specific pathogenic mechanisms, the research provides a transformative platform for studying viral tropism and evaluating antiviral strategies.

• Lopinavir (ABT-378): Quantitative Benchmarks in HIV Protease

  2026-05-27

  Lopinavir (ABT-378) is a potent HIV protease inhibitor with picomolar Ki values and robust antiviral efficacy in both wild-type and mutant strains. It outperforms ritonavir in serum-containing environments and supports advanced HIV drug resistance studies. This article provides atomic, evidence-backed insight for protocol optimization and antiretroviral research.

• Ruxolitinib Enhances oHSV-Induced Immune Activation in Murin

  2026-05-27

  The referenced study introduces a 46-color spectral flow cytometry approach to dissect immune responses in murine sarcoma following combination therapy with Ruxolitinib and oncolytic HSV. This work reveals expanded CD4 T cell and germinal center B cell activity, providing new insights for immune modulation in resistant tumors.

• Plerixafor (AMD3100): Translating CXCR4 Inhibition to Impact

  2026-05-26

  This thought-leadership article unpacks the mechanistic and translational value of Plerixafor (AMD3100) as a CXCR4 antagonist, offering strategic insights for researchers targeting cancer metastasis, hematopoietic stem cell mobilization, and immune modulation. We synthesize evidence from recent literature, benchmark competitive innovations, and provide practical guidance to empower next-generation workflows.

• Plerixafor (AMD3100): Optimizing CXCR4 Inhibition in Researc

  2026-05-26

  Plerixafor (AMD3100) stands as the benchmark for CXCR4 chemokine receptor antagonism, enabling precise control over cancer metastasis and stem cell mobilization assays. This article delivers actionable workflows, troubleshooting guidance, and strategic insights for maximizing experimental reproducibility in advanced cancer biology and immunology research.

• ARCA EGFP mRNA: High-Efficiency Reporter for Mammalian Cells

  2026-05-25

  ARCA EGFP mRNA, supplied by APExBIO, is a direct-detection reporter optimized for fluorescence-based transfection assays in mammalian cells. Its anti-reverse cap analog and extended poly(A) tail enhance translation and stability, supporting transfection efficiencies above 90%. This dossier details its rationale, mechanism, and validated use as a gold-standard mRNA transfection control.

• Paroxetine Mesylate: Applied SSRI Workflows & Oncology Insig

  2026-05-25

  Paroxetine Mesylate combines high-affinity SSRI action with multidomain kinase inhibition, powering innovative research in neuropsychology and oncology. This article unpacks practical protocols, troubleshooting strategies, and translational cross-talk for researchers leveraging this versatile compound.

• L-Ornithine and the Hepatic–Neural Axis: Mechanistic Insight

  2026-05-24

  Explore how L-Ornithine, a key urea cycle intermediate, underpins emerging research at the intersection of liver metabolism and CNS toxicity. This article delivers a mechanistic perspective distinct from prior guides, with actionable insights for advanced assay design.

14554 records 1/971 page Next 12345 下5页 Last page